News
PolyPid to Report Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights on February 9, 2022
PETACH TIKVA, Israel, Jan. 26, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today...
PolyPid Appoints UCSF Brain Tumor Center Director Mitchel S. Berger, M.D., to Oncology Advisory Board
Dr. Berger Brings Extensive Expertise in Deep Brain Tumor Treatment The Company Expects to Initiate a Phase 1/2 Clinical Trial of OncoPLEX for Brain Tumors by the end of 2022 PETAH TIKVA, Israel, Jan. 04, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the...
PolyPid Announces Planned CEO Transition
Current EVP & CFO, Dikla Czaczkes Akselbrad, Appointed CEO, Effective July 2022PETAH TIKVA, Israel, Jan. 03, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered,...
PolyPid Announces 500th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX in Abdominal Surgery
Company Continues to Expect that the Last Patient Will be Enrolled in the Second Quarter of 2022, Followed by Top-Line Results Two Months ThereafterPETAH TIKVA, Israel, Nov. 18, 2021 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a phase 3...
PolyPid Appoints New Oncology Advisory Board Member
Company is Scheduled to Conduct Pre-IND Meeting with the U.S. FDA Later This Month and Potentially Initiate Phase 1/2 Clinical Trial of OncoPLEX for Brain Tumors in 2022PETAH TIKVA, Israel, Nov. 16, 2021 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a...
PolyPid Ltd. Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Recruitment Progressing as Planned with Approximately 480 Patients Enrolled in Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Surgery Following FDA Agreement that a Single Pivotal Phase 3 Study is Sufficient for Potential Approval of D-PLEX100 for the Prevention of...
PolyPid to Report Third Quarter 2021 Financial Results and Operational Highlights on November 10, 2021
PETAH TIKVA, Israel, Nov. 01, 2021 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today...
PolyPid to Present at Upcoming Cantor Fitzgerald Global Healthcare Conference
PETAH TIKVA, Israel, Sept. 20, 2021 -- PolyPid Ltd. (Nasdaq: PYPD), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced its participation in...
PolyPid Announces Positive Preclinical Data of its Intra-tumoral OncoPLEX in Brain Cancer
Positive Results in Two Animal Models of Glioblastoma Multiform (GBM) demonstrated that Single Local Treatment of OncoPLEX Significantly Inhibited Tumor Growth and Prolonged SurvivalCompany Expects a Pre-IND Meeting with the U.S. FDA by Year End and Potential...
PolyPid to Present at First World Association Against Infection in Orthopaedics and Trauma Congress
Virtual Presentation to be led by PolyPid Co-Founder and CSO on August 28, 2021PETACH TIKVA, Israel, Aug. 17, 2021 -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma focusing on developing targeted, locally administered and prolonged-release therapeutics to...